Physicians' Academy for Cardiovascular Education

CDMC Budapest

New opportunities and directions in CV risk management: A new view on ARBs

Oct. 11, 2008

New opportunities and directions in CV risk management:
A new view on Angiotensin Receptor Blockade

Educational objectives
  • To summarise the epidemiology and ethiology of micro- and macrovascular complications in hypertensive patients, such as diabetes mellitus
  • To review and discuss the expanding role of RAS blockade across the cardiovascular continuum
  • To review the unmet medical needs in the development and progression of diabetic retinopathy and nephropathy and their potential as treatment targets
  • To discuss the results and implications of new clinical trials with ARB’s in microvascular disease in the broader perspective of current management of cardiovascular disease
  • To formulate and discuss directions for future clinical management of patients with micro-and macrovascular disorders


Agenda
 

The kidney as marker and target for CV protection: Understanding the role of RAS interventions

Prof. Hans-Henrik Parving, Copenhagen, Denmark
 

The CV continuum, when and where to intervene?
Prof. John E Deanfield, London, United Kingdom

Hypertension & the cardiorenal continuum:A closer look at ARB’s
Prof. Luis Ruilope, Madrid, Spain

The RAS and the expanding role in atherosclerosis:Relevance for Angiotensin Receptor Blockade
Prof. Thomas F. Lüscher, Zurich, Switzerland

RAS: Translating the science to clinical relevance in heart failure & macrovascular disease
Prof. Martin R Cowie, London, United Kingdom

RAS: Translating the science to clinical relevance in diabetes & microvascular disease
Dr. Ulrike Steckelings, Berlin, Germany

Diabetic retinopathy & the DIRECT study: A closer look at the results and clinical implications
Prof. Anne Katrin Sjølie, Odense, Denmark

The DIRECT study and nephropathy: Design, results and the implications
Prof. Rudy Bilous, Middlesbrough, United Kingdom

A broader view on retinopathy: What is evidence based and what are the future treatment options
Prof. Anne Katrin Sjølie, Odense, Denmark

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: